# Nuclide record lung-net (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/lung-net/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "lung-net" ;
  schema:name "Lung neuroendocrine tumours (typical and atypical carcinoid)"@en ;
  schema:alternateName "Bronchial carcinoid"@en, "Pulmonary carcinoid"@en, "Typical carcinoid"@en, "Atypical carcinoid"@en, "Lung NET"@en, "Bronchopulmonary neuroendocrine tumour"@en ;
  schema:description "Lung neuroendocrine tumours, called typical and atypical carcinoids, are slow-growing tumours of the airways that are usually cured by surgery. When they spread, everolimus is the one drug tested in a randomised trial for this site, cabozantinib was approved in 2025, and somatostatin analogues and lutetium radioligand therapy are borrowed from gut tumours."@en ;
  schema:url <https://nuclide.cc/indications/lung-net/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  schema:citation <https://doi.org/10.1016/S0140-6736(15)00817-X>, <https://doi.org/10.1056/NEJMoa2403991>, <https://en.wikipedia.org/wiki/Neuroendocrine_tumor> ;
  nuclide:tag "subtype-page", "endocrine", "lung" ;
  nuclide:related <https://nuclide.cc/indications/grade-3-net/>, <https://nuclide.cc/indications/pancreatic-net/>, <https://nuclide.cc/indications/small-intestinal-net/>, <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:technologies <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/technologies/ct/> ;
  nuclide:targets <https://nuclide.cc/targets/sstr2/> ;
  nuclide:drugs <https://nuclide.cc/drugs/everolimus/>, <https://nuclide.cc/drugs/cabozantinib/>, <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/drugs/ga68-dotatate/>, <https://nuclide.cc/drugs/pasireotide/> ;
  nuclide:terms <https://nuclide.cc/terms/net-grade-ki67/> ;
  nuclide:trials <https://nuclide.cc/trials/radiant-3-4/>, <https://nuclide.cc/trials/cabinet/>, <https://nuclide.cc/trials/nct03972488/> ;
  nuclide:keyPapers <https://nuclide.cc/key-papers/paper-cabinet-cabozantinib-nejm-2024/> ;
  nuclide:pipeline <https://nuclide.cc/trials/cabinet/>, <https://nuclide.cc/technologies/prrt/>, <https://nuclide.cc/technologies/sstr-pet/> ;
  nuclide:standardOfCare <https://nuclide.cc/technologies/ct/>, <https://nuclide.cc/technologies/sstr-pet/>, <https://nuclide.cc/drugs/ga68-dotatate/>, <https://nuclide.cc/terms/net-grade-ki67/>, <https://nuclide.cc/drugs/everolimus/>, <https://nuclide.cc/trials/radiant-3-4/>, <https://nuclide.cc/drugs/cabozantinib/>, <https://nuclide.cc/trials/cabinet/>, <https://nuclide.cc/drugs/lutathera/>, <https://nuclide.cc/technologies/prrt/> .